AXL Is a Predictor of Poor Survival and of Resistance to Anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
AXL Is a Predictor of Poor Survival and of Resistance to Anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer
Eur. J. Cancer 2020 Oct 01;138(xx)1-10, C Cardone, B Blauensteiner, V Moreno-Viedma, G Martini, V Simeon, PP Vitiello, D Ciardiello, V Belli, N Matrone, T Troiani, F Morgillo, F Zito Marino, M Dentice, A Nappi, A Boccaccino, C Antoniotti, C Cremolini, F Pietrantonio, GW Prager, N Normanno, E Maiello, G Argiles, E Elez, G Signoriello, R Franco, A Falcone, J Tabernero, M Sibilia, F Ciardiello, E MartinelliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.